Company news

InspireMD Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

June 30, 2024

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 27, 2024

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 6, 2024

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

March 25, 2024

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 5, 2024

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

February 11, 2024

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

January 30, 2024

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

January 2, 2024

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

December 19, 2023

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

November 26, 2023

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

October 31, 2023

InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

October 11, 2023

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

October 2, 2023

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

August 30, 2023

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

July 24, 2023

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

June 25, 2023

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 17, 2023

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023

InspireMD Announces Private Placement of Up to $113.6 Million

May 14, 2023

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

May 11, 2023

InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

May 4, 2023

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

April 30, 2023

InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update

April 26, 2023

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 29, 2023

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

March 19, 2023

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

March 1, 2023

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

February 13, 2023

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

November 27, 2022

InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium

November 14, 2022

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update

October 24, 2022

InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

September 12, 2022

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

August 1, 2022

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

July 13, 2022

InspireMD Reports First Quarter 2022 Financial Results and Business Update

May 9, 2022

InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

April 27, 2022

InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

March 7, 2022

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

February 27, 2022

InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

February 21, 2022

InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

February 14, 2022

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

January 17, 2022

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 8, 2021

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

November 2, 2021

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

October 25, 2021

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

October 12, 2021

InspireMD Announces Strong Second Quarter 2021 Financial Results

August 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 60 decks. Every deck is listed under its year.